All living organisms have developed a highly conserved and regulatory system, the stress system, to cope with a broad spectrum of stressful stimuli that threaten, or are perceived as threatening, their dynamic equilibrium or homeostasis. This neuroendocrine system consists of the hypothalamic-pituitary-adrenal (HPA) axis and the locus caeruleus/norepinephrine-autonomic nervous system. In parallel with the evolution of the homeostasis and stress concepts from ancient Greek to modern medicine, significant advances in the field of neuroendocrinology have identified the physiologic biochemical effector molecules of the stress response. Glucocorticoids, the end-products of the HPA axis, play a fundamental role in the maintenance of both resting and stress-related homeostasis and, undoubtedly, influence the physiologic adaptive reaction of the organism against stressors. If the stress response is dysregulated in terms of magnitude and/or duration, homeostasis is turned into cacostasis with adverse effects on many vital physiologic functions, such as growth, development, metabolism, circulation, reproduction, immune response, cognition and behavior. A strong and/or long-lasting stressor may precipitate and/or cause many acute and chronic diseases. Moreover, stressors during pre-natal, post-natal or pubertal life may have a critical impact on our expressed genome. This review describes the central and peripheral components of the stress system, provides a comprehensive overview of the stress response, and discusses the role of glucocorticoids in a broad spectrum of stress-related diseases.

Keywords:
Stress system, Stress response, Glucocorticoids, Glucocorticoid receptor, Hypothalamic-pituitary-adrenal axis
1.
Chrousos GP: Stress and disorders of the stress system. Nat Rev Endocrinol 2009;5:374-381.
2.
Chrousos GP, Gold PW: The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 1992;267:1244-1252.
3.
Charmandari E, Tsigos C, Chrousos GP: Endocrinology of the stress response. Annu Rev Physiol 2005;67:259-284.
4.
Chrousos GP, Kino T: Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007;10:213-219.
5.
Chrousos GP, Loriaux DL, Gold PW (eds): Mechanisms of Physical and Emotional Stress: Advances in Experimental Medicine and Biology. New York, Plenum Press, 1988, vol 245.
6.
Kontopoulou TD, Marketos SG: Homeostasis: the ancient Greek origin of a modern scientific principle. Hormones 2002;1:124-125.
7.
Fink G: Stress: definition and history; in Squire LR (ed): Encyclopedia of Neuroscience. Oxford, Academic Press, 2009, pp 549-555, vol 9.
8.
Selye H: A syndrome produced by diverse nocuous agents. Nature 1936;138:32.
9.
Szabo S, Tache Y, Somogyi A: The legacy of Hans Selye and the origins of stress research: a retrospective 75 years after his landmark brief ‘letter' to the editor of Nature. Stress 2012;15:472-478.
10.
Charmandari E, Kino T, Souvatzoglou E, Chrousos GP: Pediatric stress: hormonal mediators and human development. Horm Res 2003;59:161-179.
11.
Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response: the 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998;851:311-335.
12.
Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-1362.
13.
Chrousos GP, Calabrese JR, Avgerinos P, Kling MA, Rubinow D, Oldfield EH, et al: Corticotropin releasing factor: basic studies and clinical applications. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:349-359.
14.
Calogero AE, Bernardini R, Gold PW, Chrousos GP: Regulation of rat hypothalamic corticotropin-releasing hormone secretion in vitro: potential clinical implications. Adv Exp Med Biol 1988;245:167-181.
15.
Smith MA, Kling MA, Whitfield HJ, Brandt HA, Demitrack MA, Geracioti TD, Chrousos GP, Gold PW: Corticotropin-releasing hormone: from endocrinology to psychobiology. Horm Res 1989;31:66-71.
16.
Bornstein SR, Chrousos GP: Clinical review 104: Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999;84:1729-1736.
17.
Hammes SR, Levin ER: Extranuclear steroid receptors: nature and actions. Endocr Rev 2007;28:726-741.
18.
Chrousos GP, Kino T: Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005;2005:pe48.
19.
Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E: The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010;75:1-12.
20.
Lu NZ, Cidlowski JA: Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005;18:331-342.
21.
Nader N, Chrousos GP, Kino T: Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. FASEB J 2009;23:1572-1583.
22.
Nader N, Chrousos GP, Kino T: Interactions of the circadian CLOCK system and the HPA axis. Trends Endocrinol Metab 2010;21:277-286.
23.
Kino T, Chrousos GP: Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol 2011;336:23-30.
24.
Kino T, Chrousos GP: Circadian CLOCK-mediated regulation of target-tissue sensitivity to glucocorticoids: implications for cardiometabolic diseases. Endocr Dev 2011;20:116-126.
25.
Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SSM, Kino T: Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS ONE 2011;6:e25612.
26.
Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C: Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J 2012;26:4805-4820.
27.
Song IH, Buttgereit F: Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006;246:142-146.
28.
Lee SR, Kim HK, Youm JB, Dizon LA, Song IS, Jeong SH, Seo DY, Ko KS, Rhee BD, Kim N, Han J: Non-genomic effect of glucocorticoids on cardiovascular system. Pflügers Arch 2012;464:549-559.
29.
Bellavance MA, Rivest S: The neuroendocrine control of the innate immune system in health and brain diseases. Immunol Rev 2012;248:36-55.
30.
Hinz B, Hirschelmann R: Rapid non-genomic feedback effects of glucocorticoids on CRF-induced ACTH secretion in rats. Pharm Res 2000;17:1273-1277.
31.
Karst H, Berger S, Turiault M, Tronche F, Schütz G, Joëls M: Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci USA 2005;102:19204-19207.
32.
Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK: Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-479.
33.
Löwenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW: Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006;7:1023-1029.
34.
Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
35.
Groeneweg FL, Karst H, de Kloet ER, Joëls M: Rapid non-genomic effects of corticosteroids and their role in the central stress response. J Endocrinol 2011;209:153-167.
36.
Prager EM, Johnson LR: Stress at the synapse: signal transduction mechanisms of adrenal steroids at neuronal membranes. Sci Signal 2009;2:re5.
37.
Tasker JG, Di S, Malcher-Lopes R: Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 2006;147:5549-5556.
38.
Chrousos GP: The stress response and immune function: clinical implications - the 1999 Novera H. Spector lecture. Ann NY Acad Sci 2000;917:38-67.
39.
Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421-423.
40.
Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2-patterns, pro/anti- inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359-368.
41.
Elenkov IJ, Kvetnansky R, Hashiramoto A, Bakalov VK, Link AA, Zachman K, Crane M, Jezova D, Rovensky J, Dimitrov MA, Gold PW, Bonini S, Fleisher T, Chrousos GP, Wilder RL: Low- versus high-baseline epinephrine output shapes opposite innate cytokine profiles: presence of Lewis- and Fischer-like neurohormonal immune phenotypes in humans? J Immunol 2008;181:1737-1745.
42.
Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos GP: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-413.
43.
Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, Letourneau R, Rozniecki JJ, Webster E, Chrousos GP: Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 1995;136:5745-5750.
44.
Burguera B, Muruais C, Penalva A, Dieguez C, Casanueva FF: Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 1990;51:51-58.
45.
Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994;78:131-137.
46.
Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245-261.
47.
Magiakou MA, Mastorakos G, Chrousos GP: Final stature in patients with endogenous Cushing's syndrome. J Clin Endocrinol Metab 1994;79:1082-1085.
48.
Skuse D, Albanese A, Stanhope R, Gilmour J, Voss L: A new stress-related syndrome of growth failure and hyperphagia in children, associated with reversibility of growth hormone insufficiency. Lancet 1996;348:353-358.
49.
Albanese A, Hamill G, Jones J, Skuse D, Matthews DR, Stanhope R: Reversibility of physiological growth hormone secretion in children with psychosocial dwarfism. Clin Endocrinol (Oxf) 1994;40:687-692.
50.
Benker G, Raida M, Olbricht T, Wagner R, Reinhardt W, Reinwein D: TSH secretion in Cushing's syndrome: relation to glucocorticoid excess, diabetes, goitre and the ‘sick euthyroid syndrome'. Clin Endocrinol (Oxf) 1990;33:777-786.
51.
Whirledge S, Cidlowski JA: A role for glucocorticoids in stress-impaired reproduction: beyond the hypothalamus and pituitary. Endocrinology 2013;154:4450-4468.
52.
Rivier C, Rivier J, Vale W: Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science 1986;231:607-609.
53.
Vamvakopoulos NC, Chrousos GP: Hormonal regulation of human corticotropin-releasing hormone gene expression: implications for the stress response and immune/inflammatory reaction. Endocr Rev 1994;15:409-420.
54.
Chrousos GP, Torpy DJ, Gold PW: Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998;129:229-240.
55.
MacAdams MR, White RH, Chipps BE: Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-651.
56.
Luger A, Deuster PA, Kyle SB, Gallucci WT, Montgomery LC, Gold PW, Loriaux DL, Chrousos GP: Acute hypothalamic-pituitaryadrenal responses to the stress of treadmill exercise: physiologic adaptations to physical training. N Engl J Med 1987;316:1309-1315.
57.
MacConnie SE, Barkan A, Lampman RM, Schork MA, Beitins IZ: Decreased hypothalamic gonadotropin-releasing hormone secretion in male marathon runners. N Engl J Med 1986;315:411-417.
58.
Chrousos GP: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuroendocrine and target tissue-related causes. Int J Obes (London) 2000;24:s50f-s55f.
59.
Chrousos GP, Tsigos C: Stress, obesity, and metabolic syndrome. Ann NY Acad Sci 2006;1083:xi-xiii.
60.
Gold PW, Goodwin F, Chrousos GP: Clinical and biochemical manifestations of depression: relationship to the neurobiology of stress (part I). N Engl J Med 1988;319:348-353.
61.
Gold PW, Goodwin F, Chrousos GP: Clinical and biochemical manifestations of depression: relationship to the neurobiology of stress (part II). N Engl J Med 1988;319:413-420.
62.
Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry 2002;7:254-275.
63.
Chrousos G: The glucocorticoid receptor gene, longevity, and the highly prevalent complex disorders of Western societies. Am J Med 2004;117:204-207.
64.
Murgatroyd C, Wu Y, Bockmühl Y, Spengler D: Genes learn from stress: how infantile trauma programs us for depression. Epigenetics 2010;5:194-199.
65.
Meaney MJ, Aitken DH, Bodnoff SR, Iny LJ, Tatarewicz JE, Sapolsky RM: Early postnatal handling alters glucocorticoid receptor concentrations in selected brain regions. Behav Neurosci 1985;99:765-770.
66.
Meaney MJ, Aitken DH, Sapolsky RM: Thyroid hormones influence the development of hippocampal glucocorticoid receptors in the rat: a mechanism for the effects of postnatal handling on the development of the adrenocortical stress response. Neuroendocrinology 1987;45:278-283.
67.
Mitchell JB, Iny LJ, Meaney MJ: The role of serotonin in the development and environmental regulation of type II corticosteroid receptor binding in rat hippocampus. Brain Res Dev Brain Res 1990;55:231-235.
68.
Champagne FA: Early environments, glucocorticoid receptors, and behavioral epigenetics. Behav Neurosci 2013;127:628-636.
69.
Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, Sharma S, Pearson D, Plotsky PM, Meaney MJ: Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 1997;277:1659-1662.
70.
Hellstrom IC, Dhir SK, Diorio JC, Meaney MJ: Maternal licking regulates hippocampal glucocorticoid receptor transcription through a thyroid hormone-serotonin-NGFI-A signalling cascade. Philos Trans R Soc Lond B Biol Sci 2012;367:2495-2510.
71.
Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ: Epigenetic programming by maternal behavior. Nature Neuroscience 2004;7:847-854.
72.
McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, Turecki G, Meaney MJ: Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12:342-348.
73.
Stankiewicz AM, Swiergiel AH, Lisowski P: Epigenetics of stress adaptations in the brain. Brain Res Bull 2013;98:76-92.
74.
Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M: Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005;25:11045-11054.
75.
Meaney MJ: Nature, nurture, and the disunity of knowledge. Ann NY Acad Sci 2001;935:50-61.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.